Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain

Mactier, Robert; Sprosen, Timothy S.; Gokal, Ram; Williams, Paul F.; Lindbergh, Marianne; Naik, R. B.; Wrege, Ulf; Gröntoft, Knut-Christian; Larsson, Robert; Berglund, J. Andrew; Tranæus, Anders; Faict, Dirk

doi:10.1111/j.1523-1755.1998.00849.x

Cited by 140 publications

(88 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, Mactier et al. (43) undertook a randomized, double‐blind, crossover study to determine the effects of novel bicarbonate (38 mM) and bicarbonate (25 mM)/lactate (15 mM) containing peritoneal dialysis solutions on infusion pain in patients who experienced inflow pain with conventional lactate (40 mM) solution and reported an improved inflow pain reduction with the novel solutions (43).…”

Section: Strategies To Reduce the Gdp Content Of Peritoneal Dialysis mentioning

confidence: 99%

Continuous Flow Peritoneal Dialysis: Solution Formulation and Biocompatibility

Passlick–Deetjen

Lage

Jörres

2001

Seminars in Dialysis

View full text Add to dashboard Cite

When peritoneal dialysis was introduced several years ago an important alternative dialysis therapy to hemodialysis was made available for the treatment of end-stage chronic disease. However, a continuous search for new developments and technologies is necessary to find the optimal peritoneal dialysis fluid (PDF) to preserve peritoneal membrane function as long as possible. Conventional PDFs are known to compromise the functional integrity of the peritoneal membrane as a consequence of their acidic pH in combination with their high lactate content, as well as the high concentrations of glucose and glucose degradation products (GDPs) present in currently used conventional solutions. Novel solutions such as bicarbonate-buffered PDF (at neutral pH) display improved in vitro biocompatibility as compared to conventional, acidic lactate-buffered PDF. Since these novel solutions are manufactured in dual-chambered bags they also contain fewer GDPs, thus further reducing their potential toxicity and protein glycation. Clinically the novel solutions reduce inflow pain and improve peritoneal membrane transport characteristics, ultrafiltration capacity, and effluent markers of peritoneal membrane integrity. The concept of continuous flow peritoneal dialysis (CFPD) is another approach to optimize PDF. The technique of CFPD not only enables the individualization of acid-base correction by variable concentrations of HCO3- but may also help to restore peritoneal cell functions by neutral pH, reduced glucose load, diminished GDP content, and reduced advanced glycation end product (AGE) formation, thereby potentially contributing to the improved preservation of peritoneal membrane function.

show abstract

Section: Strategies To Reduce the Gdp Content Of Peritoneal Dialysis mentioning

confidence: 99%

Continuous Flow Peritoneal Dialysis: Solution Formulation and Biocompatibility

Passlick–Deetjen

Lage

Jörres

2001

Seminars in Dialysis

View full text Add to dashboard Cite

show abstract

“…[21][22][23] Solutions using bicarbonate or bicarbonate-lactate mixtures result in significantly less infusion pain and are as effective as lactate at correction of acidosis when they are used at the same total buffer ion concentration. 24 In prospective, randomized studies, these fluids have been associated with improvement in dialysate effluent markers of peritoneal membrane integrity, particularly cancer antigen 125 (CA-125), a measure of peritoneal mesothelial cell mass. [21][22][23] There have also been some indications of improved residual renal function in patients with PD solutions low in GDPs, 23 although this was not confirmed in a prospective randomized study.…”

Section: Techniques Of Peritoneal Dialysismentioning

confidence: 99%

Peritoneal Dialysis

Rippe¹

2010

Comprehensive Clinical Nephrology

View full text Add to dashboard Cite

“…If the discomfort occurs with complete draining of the peritoneal cavity, it may be alleviated by changing the patient to tidal PD (27). Pain due to the acidity of the PD fluid may decrease with neutralization of the pH (22,28).…”

Section: Management Of Noncompliancementioning

confidence: 99%

Automated Peritoneal Dialysis Symposium: Role of APD in Compliance with Therapy

Raj

2002

Seminars in Dialysis

View full text Add to dashboard Cite

Lack of compliance with prescribed treatment is an important cause of inadequate dialysis in patients on peritoneal dialysis (PD). The reported prevalence of noncompliance with treatment in PD varies from 5 to 38%. The predictors of noncompliance, its consequences, methods to identify and monitor compliance, differences in frequency between continuous ambulatory PD (CAPD) and automated PD (APD), and management are reviewed. The risk of noncompliance is greater in CAPD than in APD. Noncompliance should be managed by patient education and appropriate modification of therapy, including consideration of APD.

show abstract

Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain

Cited by 140 publications

References 14 publications

Continuous Flow Peritoneal Dialysis: Solution Formulation and Biocompatibility

Continuous Flow Peritoneal Dialysis: Solution Formulation and Biocompatibility

Peritoneal Dialysis

Automated Peritoneal Dialysis Symposium: Role of APD in Compliance with Therapy

Contact Info

Product

Resources

About